Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay. Burutaran, M. B., Guadagna, R., Grille, S., Stevenazzi, M., Guillermo, C., & Diaz, L. Revista Brasileira de Hematologia e Hemoterapia, 37:28–33, February, 2015. Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular![Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of 63% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.
@article{burutaran_results_2015,
title = {Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in {Uruguay}},
volume = {37},
issn = {1516-8484, 1806-0870},
url = {https://www.scielo.br/j/rbhh/a/zv4nR8VvbqjLV3PCCvjzRkD/?format=html&lang=en},
doi = {10.1016/j.bjhh.2014.11.012},
abstract = {Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4\%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3\% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3\%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5\% of all microbiologically documented infections. Treatment of 63\% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5\%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.},
language = {en},
urldate = {2024-10-08},
journal = {Revista Brasileira de Hematologia e Hemoterapia},
author = {Burutaran, Matilde Boada and Guadagna, Regina and Grille, Sofia and Stevenazzi, Mariana and Guillermo, Cecilia and Diaz, Lilian},
month = feb,
year = {2015},
note = {Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular},
keywords = {Drug resistance, Gram-negative bacterial infections, Hematologic diseases, Neutropenia Clinical protocols, bacterial},
pages = {28--33},
}
Downloads: 0
{"_id":"aMSm3bgbHuC3ZDryf","bibbaseid":"burutaran-guadagna-grille-stevenazzi-guillermo-diaz-resultsofhighriskneutropeniatherapyofhematologyoncologypatientsinauniversityhospitalinuruguay-2015","author_short":["Burutaran, M. B.","Guadagna, R.","Grille, S.","Stevenazzi, M.","Guillermo, C.","Diaz, L."],"bibdata":{"bibtype":"article","type":"article","title":"Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay","volume":"37","issn":"1516-8484, 1806-0870","url":"https://www.scielo.br/j/rbhh/a/zv4nR8VvbqjLV3PCCvjzRkD/?format=html&lang=en","doi":"10.1016/j.bjhh.2014.11.012","abstract":"Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of 63% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.","language":"en","urldate":"2024-10-08","journal":"Revista Brasileira de Hematologia e Hemoterapia","author":[{"propositions":[],"lastnames":["Burutaran"],"firstnames":["Matilde","Boada"],"suffixes":[]},{"propositions":[],"lastnames":["Guadagna"],"firstnames":["Regina"],"suffixes":[]},{"propositions":[],"lastnames":["Grille"],"firstnames":["Sofia"],"suffixes":[]},{"propositions":[],"lastnames":["Stevenazzi"],"firstnames":["Mariana"],"suffixes":[]},{"propositions":[],"lastnames":["Guillermo"],"firstnames":["Cecilia"],"suffixes":[]},{"propositions":[],"lastnames":["Diaz"],"firstnames":["Lilian"],"suffixes":[]}],"month":"February","year":"2015","note":"Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular","keywords":"Drug resistance, Gram-negative bacterial infections, Hematologic diseases, Neutropenia Clinical protocols, bacterial","pages":"28–33","bibtex":"@article{burutaran_results_2015,\n\ttitle = {Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in {Uruguay}},\n\tvolume = {37},\n\tissn = {1516-8484, 1806-0870},\n\turl = {https://www.scielo.br/j/rbhh/a/zv4nR8VvbqjLV3PCCvjzRkD/?format=html&lang=en},\n\tdoi = {10.1016/j.bjhh.2014.11.012},\n\tabstract = {Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4\\%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3\\% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3\\%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5\\% of all microbiologically documented infections. Treatment of 63\\% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5\\%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.},\n\tlanguage = {en},\n\turldate = {2024-10-08},\n\tjournal = {Revista Brasileira de Hematologia e Hemoterapia},\n\tauthor = {Burutaran, Matilde Boada and Guadagna, Regina and Grille, Sofia and Stevenazzi, Mariana and Guillermo, Cecilia and Diaz, Lilian},\n\tmonth = feb,\n\tyear = {2015},\n\tnote = {Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular},\n\tkeywords = {Drug resistance, Gram-negative bacterial infections, Hematologic diseases, Neutropenia Clinical protocols, bacterial},\n\tpages = {28--33},\n}\n\n\n\n","author_short":["Burutaran, M. B.","Guadagna, R.","Grille, S.","Stevenazzi, M.","Guillermo, C.","Diaz, L."],"key":"burutaran_results_2015","id":"burutaran_results_2015","bibbaseid":"burutaran-guadagna-grille-stevenazzi-guillermo-diaz-resultsofhighriskneutropeniatherapyofhematologyoncologypatientsinauniversityhospitalinuruguay-2015","role":"author","urls":{"Paper":"https://www.scielo.br/j/rbhh/a/zv4nR8VvbqjLV3PCCvjzRkD/?format=html&lang=en"},"keyword":["Drug resistance","Gram-negative bacterial infections","Hematologic diseases","Neutropenia Clinical protocols","bacterial"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/apolea","dataSources":["f9QNc6eirHM3cmhSh"],"keywords":["drug resistance","gram-negative bacterial infections","hematologic diseases","neutropenia clinical protocols","bacterial"],"search_terms":["results","high","risk","neutropenia","therapy","hematology","oncology","patients","university","hospital","uruguay","burutaran","guadagna","grille","stevenazzi","guillermo","diaz"],"title":"Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay","year":2015}